Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 19, 2017
Pharmacy Choice - Pharmaceutical News - Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) To Dispose Of Contraceptive Paragard To Repay Debt - November 19, 2017

Pharmacy News Article

 9/12/17 - Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) To Dispose Of Contraceptive Paragard To Repay Debt

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has announced that it will dispose of Paragard, a contraceptive brand, to a Cooper Cos unit at a price of $1.1 billion. This was on the same day that Kare Schultz was named as the chief executive officer of the Israeli pharmaceutical giant.

Selling Paragard constitutes one of the first steps Teva is making as it gets rid of non-core assets. Proceeds from the sale of such assets will be used in repaying debt. Currently the generics drugmaker has debt amounting $35 billion. After the twin announcements shares of the pharmaceutical firm went up. Since Teva cut its forecasts last month, the U.S.-listed stock of the generics drugmaker has fallen by half.

Divestiture opportunities

Investors will like this news, as in addition to a good price for the asset, and the recent share decline has been likely due in part to investor worries that the debt burden is high, wrote David Maris, an analyst at Wells Fargo Securities in a client note.

While making the announcement of the sale of Paragard, Teva said that divestiture opportunities would continue to be assessed and this included selling the assets that remain from its worldwide women's health business. It is also considering selling its pain and oncology businesses in Europe. According to Teva the sale of these assets as well as other assets would generate about $2 billion. These sales are expected to have been concluded by the end of this calendar year.

New York plant

In the Paragard sale, Teva's New York manufacturing facility which makes the contraceptive exclusively will also be part of the deal. Revenues from Paragard in the fiscal year which ended three months ago amounted to $168 million. Before the deal is concluded Teva would keep on manufacturing and selling the contraceptive in the U.S.

After the divesting efforts have ended, Teva will focus on Respiratory and CNS as the key therapeutic areas globally. The generic drugmaker has a strong portfolio and pipeline globally in these areas and will keep on investing in the creation of long term value.

On Monday shares of Teva Pharmaceutical Industries jumped by 19.35% to close the day at $18.50.

The post Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) To Dispose Of Contraceptive Paragard To Repay Debt appeared first on Market Exclusive.

© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement